HC Wainwright Issues Positive Forecast for CATX Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for shares of Perspective Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.18) EPS.

Several other research analysts have also commented on the company. Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Finally, Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Stock Down 8.2 %

Shares of CATX opened at $1.80 on Thursday. The company has a 50 day moving average price of $2.77 and a 200-day moving average price of $5.97. Perspective Therapeutics has a fifty-two week low of $1.79 and a fifty-two week high of $19.05.

Institutional Trading of Perspective Therapeutics

Large investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Perspective Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock worth $224,000 after purchasing an additional 11,472 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in Perspective Therapeutics during the 4th quarter worth about $1,595,000. Squarepoint Ops LLC purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $626,000. Wexford Capital LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $64,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $484,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other news, CFO Juan Graham bought 33,333 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert F. Williamson III purchased 22,192 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the acquisition, the director now owns 70,837 shares in the company, valued at $160,799.99. This trade represents a 45.62 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 115,696 shares of company stock worth $256,344. 3.52% of the stock is owned by corporate insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.